Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as NR2B NMDA Antagonist CP-101,606 (traxoprodil)
NR2B NMDA Antagonist CP-101, 606 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| NR2B NMDA Antagonist CP-101,606 (traxoprodil) | DRUG | - |
Inclusion Criteria: * 30- 80-year-old PD patients (UK Parkinson's Disease Brain Bank criteria) with a Hoehn \& Yahr stage score of 2-5 in the "off" state. Exclusion Criteria: * Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal...
Top 12 of 19 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 2 | PHASE3 | Onapgo (SPN-830) |
| Prothena Corp. Plc | PRTA | 3 | PHASE3 | Prasinezumab |
| Biohaven Ltd. | BHVN | 1 | PHASE2 | BHV-8000 |
| Denali Therapeutics Inc. | DNLI | 1 | PHASE2 | BIIB122 |
| AC Immune SA | ACIU | 2 | PHASE2 | ACI-7104.056 |
| Gain Therapeutics, Inc. | GANX | 2 | PHASE2 | GT-02287 |
| Eli Lilly and Company | LLY | 3 | PHASE1 | LY3884961, LY4006896, LY3962681 |
| Annovis Bio Inc | ANVS | 1 | PHASE2 | Buntanetap |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | ALN-SNCA |
| MeiraGTx Holdings Plc | MGTX | 1 | PHASE1 | AAV-GAD |
| AgeX Therapeutics, Inc. | SER | 1 | PHASE1 | SER-252 |
| Ardelyx, Inc. | ARDX | 1 | PHASE2 | Tenapanor |
NR2B NMDA Antagonist CP-101,606 is an investigational small molecule developed by Pfizer, Inc. (ticker PFE) for Parkinson's Disease. It is also known as traxoprodil. It has been studied in a Phase 2 clinical trial and is not an approved therapy; it remains in clinical development.
NR2B NMDA Antagonist CP-101,606 has been studied for Parkinson's Disease, a neurological condition. The single completed Phase 2 trial enrolled 12 patients with Parkinson's Disease in the United States. No approved use has been established for this investigational agent.
NR2B NMDA Antagonist CP-101,606 targets the NR2B subunit of the NMDA receptor. By acting on this subunit, the small molecule is designed to modulate NMDA receptor signaling. This target class places it among NR2B-selective NMDA antagonists being explored in neurology.
Pfizer, Inc. (ticker PFE) is the developer of NR2B NMDA Antagonist CP-101,606, also known as traxoprodil. Pfizer sponsored the Phase 2 study of the compound in Parkinson's Disease conducted in the United States.
NR2B NMDA Antagonist CP-101,606 is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The drug is investigational and has not been approved by the FDA for any indication.
NR2B NMDA Antagonist CP-101,606 was evaluated in the completed Phase 2 trial NCT00163085, titled "The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease." The randomized, double-blind study enrolled 12 participants aged 30 years and older in the United States.
Yes, NR2B NMDA Antagonist CP-101,606 is also known as traxoprodil. The two names refer to the same investigational small molecule developed by Pfizer, Inc. (ticker PFE) and studied in Phase 2 for Parkinson's Disease under NCT00163085.